长春瑞滨加顺铂治疗晚期非小细胞肺癌的临床观察：附46例报告

目的：观察长春瑞滨加顺铂（ＮＰ方案）治疗晚期非小细胞肺癌（ＮＳＣＬＣ）的疗效。方法：８６例晚期ＮＳＣＬＣ患者随机分成ＮＰ方案组（４６例）和丝裂霉素加长春地辛加顺铂（ＭＶＰ方案）组（４０例）。每例至少治疗２周期。结果：ＮＰ组和ＭＶＰ组的有效率分别为４１％和３０％（Ｐ〉０．０５）,中位缓解期分别为３．０个月和２．６个月（Ｐ〉０．０５）,中位生存期分别为７．８个月和６．５个月（Ｐ〉０．０５）。主要不良反     

MVP,NP方案治疗非小细胞肺癌疗效比较

目的 观察抗肿瘤药物丝裂霉素（ＭＭＣ）、西艾克（ＶＤＳ）和顺铂（ＰＤＤ）组成了ＭＶＰ方案和若维本（ＮＶＢ）顺铂（ＰＤＤ）组成的ＮＰ方案治疗晚期非小细胞肺癌的近期儿和毒性反应。方法 治疗晚期非小细胞肺癌１２３例,用ＭＶＰ方案治疗７２例,用ＮＰ方案治疗５１例,比较毒副反应及疗效。结果 有效率ＭＶＰ组为４３．５％,ＮＰ组为４９．０％,两组比较有效率相近（Ｘ＾２＝０．４３ Ｐ〉０．０５）。毒副反应主要为骨     

药物加运动疗法对老年晚期非小细胞肺癌患者的疗效观察

目的探讨药物加运动疗法治疗老年人晚期非小细胞肺癌（ＮＳＣＬＣ）康复疗效。方法将７２例老年晚期ＮＳＣＬＣ病人随机分成２组。治疗组：应用紫杉醇（太素 １００－１３５ｍｇ／ｍ２）加卡铂（２００ｍｇ／ｍ２）化疗２周期,胸部放疗６０Ｇｙ（３０次,每周５次）,放疗时每周加用３０ｍｇ紫杉醇,辅用心理疗法和功能锻炼。对照组：应用ＣＥ方案加放疗。结果治疗组近期有效率为６０．０％,对照组为３４．３％,两组差异显著（Ｐ＜０．０５）,ＮＰＳ评分提高率：治疗组较对照组有显著差异（Ｐ＜０．０５）。结论药物加运动综合治疗对老年晚期ＮＳＣＬＣ康复更有利。     

失碳长春碱或长春花碱酰胺加顺铂治疗晚期非小细胞肺癌临床观察

目的：观察失碳长春碱（ＮＶＢ）加顺铂（ＤＤＰ）与长春花碱酰胺（ＶＤＳ）加顺铂两种联合化疗方案治疗晚期非小细胞肺癌（ＮＳＣＬＣ）的疗效及毒性反应。方法：对收治的７６例ＮＳＣＬＣ患者随机分成两组,Ａ组（ｎ＝３８）：ＮＶＢ ２５ｍｇ／ｍ＾２＋生理盐水８０～１００ｍｌ于第１天,第８天或第５天静注,ＤＤＰ８０～１００ｍｇ／ｍ＾２＋２．５％氯化钠２５０～５００ｍｌ于第１天或分５ｄ静点。Ｂ组（ｎ＝３８）：ＶＤＳ     

不同剂量肾上腺素对心脏骤停者心肺复苏效果的影响（附71例分析）

对７１例心脏骤停患者行心肺复苏术的同时，给予三种不同剂量肾上腺素弹丸式静脉注射，结果大剂量肾上腺素组（０．１ｍｇ／ｋｇ／次）心律恢复率７０．３３％，血压恢复率６２．５％，呼吸恢复率４１．７６％，与中剂量组（１．０ｍｇ／首次￣０．１ｍｇ／ｋｇ／次）相近，显著高于小剂量组（０．５￣１．０ｍｇ／次，Ｐ〈０．０５）；大剂量组存活出院率３３．３３％，明显高于另两组（Ｐ〈０．０５）。结果提示，在对心脏骤停者进     

吉西他滨联合奈达铂治疗晚期非小细胞肺癌疗效评价

目的探讨吉西他滨联合奈达铂治疗晚期非小细胞肺癌的临床疗效。方法72例晚期非小细胞肺癌患者随机分为奈达铂组38例,顺铂组34例。奈达铂组：奈达铂组40nag加入0．9％氯化钠溶液500mL,静滴2小时,第1～3天。顺铂组40mg加入0．9％氯化钠溶液500mL,静滴2小时,第1～3天;两组中吉西他滨800mg／m2,第1、8天。溶于0．9％氯化钠溶液100mL,静滴0．5h。2周期化疗后评估疗效及不良反应。结果奈达铂组总有效率为34．2％,顺铂组总有效率为34．6％,两组比较差异无显著性（P〉0．05）。奈达铂组血液学毒性较顺铂组严重,而消化道反应则较顺铂组轻。结论奈达铂联合吉西他滨与顺铂联合吉西他滨对晚期非小细胞肺癌临床疗效相当,奈达铂的消化道反应明显低于顺铂。     

长春瑞宾联合顺铂、卡铂、奥沙利铂在治疗晚期非小细胞肺癌的比较

目的：观察长春瑞宾分别联合顺铂、卡铂、奥沙利铂治疗晚期非小细胞肺癌的临床疗效、安全性及毒副反应。方法：全部156例经病理学和／或细胞学证实的Ⅲb～Ⅳ期非小细胞肺癌（NSCLC）患者，年龄在35～79岁，Karnofsky评分为≥70分；给予盖诺25mg／m^2静脉推注，第1、8天，顺铂75mg～80mg／m^2，分为第1、2、3天静脉滴注，每3周重复。2周期后评价疗效与毒副反应。结果：156例患者中，完全缓解（CR）5例，部分缓解（PR）67例，稳定（SD）41例，进展（PD）43例；总有效率为46．1％。长春瑞滨联合顺铂组有效率为48．4％。部分缓解率为45．2％；长春瑞宾联合卡铂组有效率为47．2％，部分缓解率43．3％；长春瑞滨联合奥沙利铂组有效率为41．5％。部分缓解率为39％，各组近期疗效比较无显著性差异（P〉0．05）。主要毒副反应为骨髓抑制．胃肠道反应及神经毒性。结论：长春瑞宾分别联合顺铂／卡铂／奥沙利铂治疗晚期非小细胞肺癌的近期疗效无明显差异。     

非小细胞肺癌的姑息手术放疗140例分析

１９８６年７月至１９９０年７月，１４０例肺癌姑息术后，７０例行术后放疗，７０例对照。５年生存率率后放疗组２８．６％，对照组５．７％（Ｐ〈０．０５）。局部复发率放疗组１２．８％，对照组４２．９％（Ｐ〈０．０５）。两组远地转移无差异，放疗剂量以５０￣６０Ｇｙ／５￣６Ｗ的５年生存率最好，为３８．９％。     

诺维苯加顺铂治疗晚期非小细胞肺癌21例疗效分析

目的：观察诺维苯加顺铂治疗晚期非小细胞肺癌的近期疗效和不良反应。方法：诺维苯(NVB)25mg／m^2第1、8天用，顺铂(DDP)25mg／m^2第2～4天用。结果：有效率(CR PR)达42．9％(9／12)，毒性反应表现为骨髓抑制和胃肠道反应。结论：NVB DDP治疗晚期非小细胞肺癌的近期疗效肯定，毒性反应可以耐受，可以作为一线化疗方案。     

缬沙坦治疗轻、中度原发性高血压的临床研究——附117例报告

目的：评价缬沙坦治疗轻、中度原发性高血压的临床疗效及安全性。方法：缬沙坦组（５９例，８０ｍｇ／ｄ及１６０ｍｇ／ｄ）和氯沙坦组（对照组，５８例，５０ｍｇ／ｄ至１００ｍｇ／ｄ）均边续服药半年。结果：两组总有效率、降压幅度、收缩压和舒张压的谷／峰比值分别为７５％和７４％、３．５ｋＰａ／２．０ｋＰａ和３．４ｋＰａ／２．１ｋＰａ、０．８２和０．８１、０．７８和０．７９，组间比较均无显著性差异（Ｐ〉０．０５）；两组治疗后血浆贤素活性、血管紧张素Ⅱ均升高（Ｐ〈０．０５～０．０１）；醛固酮、内皮素均降低（均为Ｐ〈０．０５），但组间比较无显著性差异（Ｐ〉０．０５）。血尿酸也明显下降（均为Ｐ〈０．０５），基础值越高，降幅越大，且氯沙坦组更显著（Ｐ〈０．０５）。随访半年，两组心、脑血管事件发生率相似（Ｐ〉０．０５），两组不良反应轻微     

Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors

BACKGROUND: Previous studies have reported a synergistic effect between irinotecan and cisplatin. We have conducted a phase I trial combining these agents to find the optimal dose of irinotecan in combination with a fixed dose of cisplatin. METHODS: Patients with advanced solid tumors, aged < or =75 years, performance status < or =2, and adequate organ function were enrolled in this study. They were treated at 4-week intervals with irinotecan plus 20 mg/m(2) cisplatin on days 1, 8, and 15. The starting dose of irinotecan of 40 mg/m(2) was escalated in 10 mg/m(2) increments until a maximum dose of 90 mg/m(2) was reached. RESULTS: The recommended dose for phase II studies is 90 mg/m(2) of irinotecan and 20 mg/m(2) of cisplatin on days 1, 8, and 15. Overall response to the chemotherapy was 35% (95% confidential interval, 19.2-54.6%). CONCLUSION: This combination seems to be active against lung cancer with acceptable toxicity. A phase II study is now ongoing.     

A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer

BACKGROUND: Gemcitabine is widely accepted as the first-line agent for advanced pancreatic cancer. The antitumor cell activity of gemcitabine is higher when administered after 5-fluorouracil (5-FU) rather than before 5-FU in an in vitro study. The present study was conducted to define the maximum tolerated dose and dose-limiting toxicity associated with an oral fluoropyrimidine prodrug that combines uracil and tegafur (UFT), given prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer. METHODS: Over a 21-day cycle, gemcitabine was given intravenously over 30 min on days 8 and 15, while UFT was given orally from days 1 to 14. The dose of UFT used was 400 mg per day, given as two doses. The dose of gemcitabine was escalated in a stepwise fashion from 800 (level 1, n = 3) to 900 mg/m2 (level 2, n = 6) and then to 1,000 mg/m2 (level 3, n = 3), such that totally 12 patients received the combination chemotherapy. RESULTS: During the first cycle, grade 3 leukopenia was observed in 2 patients at dose level 1. Only 1 patient treated at dose level 2 experienced dose-limiting toxicity (grade 3 elevated transaminase), including additional patients treated at this dose level. No grade 3/4 toxicities occurred in patients treated at dose level 3. A significant response was observed in 1 out of 12 patients (8.3%). Seven patients (58.3%) had stable disease, while 4 patients (33.3%) showed disease progression. CONCLUSIONS: The combination chemotherapy of oral UFT and gemcitabine was convenient, well tolerated and may benefit patients with advanced pancreatic cancer. Doses recommended for further study of this schedule are gemcitabine 1,000 mg/m2 and UFT 400 mg/day.     

国产奈达铂联合吉西他滨治疗晚期非小细胞肺癌临床研究

目的：观察国产奈达铂联合吉西他滨治疗中晚期非小细胞肺癌的疗效和毒副反应。方法：27例不能手术的Ⅲ～Ⅳ期非小细胞肺癌患者，应用奈达铂80～100mg/m2，静脉滴注，d1，吉西他滨1000mg/m2，静脉滴注，d1、d8、d15，28天为1个周期，用药3个周期后进行评价，并观察同期采用顺铂联合吉西他滨化疗的Ⅲ～Ⅳ期非小细胞肺癌患者35例作为对照。结果：奈达铂组27例，CR1例，PR10例，NC11例，PD5例，总有效率（CR+PR）为40.7％（11/27），顺铂组总有效率42.9%（15/35）；中位生存时间奈达铂组6.6个月，顺铂组6.7个月，无明显差异（P〉0.05）；奈达铂主要毒副反应的为骨髓抑制，白细胞下降74.1%，但Ⅲ～Ⅳ度下降为29.6%，其次是消化道反应，未发现明显的肝肾毒性、周围神经毒性等。结论：奈达铂联合国产吉西他滨治疗中晚期非小细胞肺癌疗效与顺铂联合吉西他滨疗效相当，但毒副反应减轻，耐受性好。     

紫杉醇／顺铂同步化疗加后程加速超分割放射治疗局部晚期非小细胞肺癌的临床观察

【目的】探讨紫杉醇／顺铂同步化疗加后程加速超分割放射治疗晚期非小细胞肺癌（NSCLC）的疗效及副反应。【方法】将64例局部晚期NSCLC患者随机分为化放组和单放组,每组32例。化放组采用化疗方案为紫杉醇顺铂同步化疗加后程加速超分割放射治疗,Co体外照射在化疗开始时同步进行。单放组仅采用后程加速超分割放射治疗。【结果】总有效率、2年生存率两组间比较差异有统计学意义（P〈0．05）。化放组白细胞减少发生率、脱发发生率与单放组比较差异有统计学意义（P〈0．05）;化放纽放射性食管炎、放射性肺炎发生率与单放组比较,差异无统计学意义（P〉0．05）。【结论】紫杉醇／顺铂同期化疗合并后程加速超分割放射治疗局部晚期NSCLC能提高近期疗效,患者在粒细胞集落刺激因子等支持治疗下,毒副反应可以耐受。     

替吉奥联合草酸铂治疗晚期胃癌临床研究

目的观察替吉奥(S-1)联合草酸铂(L-OHP)治疗晚期胃癌的临床疗效及安全性。方法将64例晚期胃癌患者随机分成试验组和对照组。试验组患者采用替吉奥60 mg,早晚各服1次,第1～14天,草酸铂130 mg/m2,静脉滴注1 d;对照组患者给予氟尿嘧啶联合顺铂化疗方案,氟尿嘧啶750 mg/d,静脉滴注,第1～5天,顺铂40 mg/d,静脉滴注,第1～3天。21 d为1个周期,至少连用2个周期后评价疗效。结果试验组完全缓解(CR)1例,部分缓解(PR)17例,稳定(SD)12例,进展(PD)2例。有效率(RR)为56.3%。不良反应较轻,主要表现为Ⅰ～Ⅱ度恶心、呕吐、腹泻等胃肠道反应,手足综合征,末梢神经感觉异常及血液学毒性。结论替吉奥联合草酸铂治疗晚期胃癌具有较好的疗效,能显著提高患者的生活质量。     

A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting

 Fractionated cisplatin-containing regimens are routinely used for chemotherapy in certain types of cancer. Dolasetron has been shown to be effective in preventing acute emesis related to high-dose cisplatin chemotherapy over 24 h; its effectiveness has not been evaluated in fractionated cisplatin-containing chemotherapy. This trial was designed to assess the efficacy of dolasetron alone or dolasetron plus dexamethasone in preventing nausea and vomiting related to fractionated cisplatin chemotherapy. The patients were 210 cancer in-patients, who were randomised to receive 100 mg dolasetron i.v. or 100 mg dolasetron i.v. plus 20 mg dexamethasone before chemotherapy primarily with cisplatin (15–50 mg/m²) infused over ≤4 h for at least 2 but not more than 5 consecutive days. Dolasetron was administered to all patients 30 min before cisplatin. Dexamethasone was administered in double-blind fashion 5 min before cisplatin. Efficacy was measured at hour 24 of each study day using complete response (no vomiting and no rescue medication) and maximum severity of nausea, self-assessed by patients using a 100-mm visual analogue scale. Most (198) of the patients completed the study and were evaluable. Overall complete response rates were significantly higher in the dolasetron plus dexamethasone group than in the dolasetron only group (72.9% vs 40.8%, respectively; P<0.0001). Complete response rates on each study day were also significantly higher with dolasetron plus dexamethasone than with dolasetron alone (P<0.029), with an attenuated efficacy in the delayed phase in both groups. Chi-square test and logistic regression applied to daily response rates indicated a significant influence of treatment (day 1: P=0.0002, day 2: P<0.0001, day 3: P=0.0007, day 4: P=0. 0007, day 5: P=0.029). Treatment and duration of chemotherapy exerted the only statistically significant subgroup effects on complete response (P<0.0001). Both treatments were administered safely. As seen with other 5-HT₃ receptor antagonist antiemetics, the addition of dexamethasone to dolasetron significantly increases effectiveness in preventing nausea and vomiting related to fractionated cisplatin chemotherapy. Both dolasetron and dolasetron plus dexamethasone were well tolerated. Published online: 19 August 1999     

Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer

Based on the role of cytokines in the pathogenesis of cancer-related anorexia-cachexia and the ability of progestins, such as medroxyprogesterone acetate, to reduce cytokine production and relieve cancer-related anorexia-cachexia symptoms, the authors designed an open, dose-finding phase I study of a combined chemotherapy regimen (cisplatin [CDDP], epidoxorubicin [EPI]), including recombinant interleukin-2 (IL-2) and medroxyprogesterone acetate for patients with stage IIIB to IV inoperable primary lung cancer. The end points were clinical response and toxicity with definition of dose-limiting toxicity and maximal tolerable dose; relief of cancer-related anorexia-cachexia symptoms; the assessment of patient serum levels of IL-1beta, IL-6, tumor-necrosing factor-alpha (TNF-alpha), and soluble IL-2 receptor (sIL-2R). From March to October 1997, 16 patients (M:F ratio, 14:2; mean age, 60.5 years; age range, 41 to 74 years) were enrolled. All patients were evaluable for toxicity and 14 of them for response. The patients were assigned to increasing dose levels of drugs according to a dose-escalation schedule. The weekly schedule consisted of a combination of CDDP given intravenously on day 1, EPI given intravenously on day 1, 1 g/day medroxyprogesterone acetate given orally on days 1 to 7, and recombinant IL-2 1.8 MIU administered subcutaneously on days 2 to 7 plus 300 microg granulocyte-colony stimulating factor support given subcutaneously on days 2 to 5. Administration of medroxyprogesterone acetate began 1 week before the first cycle. Dose escalation of the drugs was as follows: 30 mg x m2 x week(-1) CDDP and 25 mg x m2 x week(-1) EPI (first level, two patients); 30 mg x m2 x week(-1) CDDP and 33 mg x m2 x week(-1) EPI (second level, 2 patients); 40 mg x m2 x week(-1) CDDP and 33 mg x m2 x week(-1) EPI (third level, 6 patients); and 40 mg x m2 x week(-1) CDDP and 40 mg x m2 x week(-1) EPI (fourth level, 6 patients). Six cycles were planned for each patient. The actual dose intensity delivered was more than 80% of the projected dose intensity of all drugs. After six cycles, clinical response (according to World Health Organization criteria), toxicity (according to World Health Organization criteria), Eastern Cooperative Oncology Group (ECOG) performance status, body weight, appetite, and serum levels of cytokines were evaluated. After six cycles, 9 of 14 patients (64.3%) had partial response, 3 of 14 (21.4%) had stable disease, and 2 of 14 (14.3%) had progressive disease, and the objective response rate was 64.3%. ECOG performance status and body weight did not change significantly after treatment, whereas appetite showed an increase that was of borderline statistical significance. Toxicity was acceptable and only hematologic. Dose-limiting toxicity was established at the fourth dose level; consequently, maximal tolerable dose was assessed at the third dose level. Before treatment, the serum levels of IL-1beta, IL-6, and TNF-alpha were significantly greater in the patients than in healthy persons. The comparison between pretreatment and posttreatment serum values of IL-1beta, IL-6, TNF-alpha, and sIL-2R did not reveal significant differences in the patients. Similar results were obtained when the patients were considered as responders (partial response) or non-responders (stable or progressive disease) to therapy. Only IL-6 serum levels were increased (p = 0.014) after treatment.     

吉西他滨联合腹腔热灌注化疗治疗晚期胰腺癌疗效观察

目的观察吉西他滨联合腹腔热灌注化疗治疗晚期胰腺癌的临床疗效及安全性。方法选择晚期胰腺癌患者44例,随机化分为两组,其中试验组22例,接受吉西他滨1000 mg/m2,d1、d8,腹腔热灌注生理盐水500 mL＋顺铂40 mg/m2,d2、d5、d9;对照组22例,接受吉西他滨1000 mg/m2,静脉滴注,d1、d8＋顺铂40 mg/m2,静脉滴注,d1~3,两组均21 d为1周期,接受治疗2个周期后评价疗效。结果41例患者可进行疗效评估,两组临床疗效比较,试验组稳定率61.90%显著高于对照组稳定率45.00%,差异有统计学意义（P＜0.05）;临床收益反应比较,实验组有效率85.7%也明显高于对照组为50.0%,差异有统计学意义（P ＜0.05）。结论吉西他滨联合腹腔热灌注化疗治疗晚期胰腺癌疗效较好,毒副反应小,止痛效果明显。     

Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study

Background: Palliative chemotherapy is currently the primary therapeutic approach in the treatment of advanced biliary tract cancer (BTC). Our aim was to assess the efficacy and safety of capecitabine plus cisplatin as first-line chemotherapy for patients with advanced BTC and to analyze the relationship between the level of CA19-9 and clinical outcome. Methods: We retrospectively reviewed the records of patients who had unresectable, metastatic or recurrent BTC who were treated with capecitabine plus cisplatin. Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period. Cisplatin was administered intravenously on days 1 and 8 at a dose of 30 mg/m(2) for 60 min every 3 weeks. Results: A total of 176 patients were enrolled. Among the 143 assessable patients, 24 (17%) had a partial response. A complete response was radiologically confirmed in 1 patient who had gallbladder cancer. Sixty-two patients (43%) had stable disease and 56 patients (39%) had progressive disease. With a median follow-up of 5.7 months, the median time-to-progression (TTP) was 3.7 months (95% CI 3.1-4.3) and the median overall survival (OS) was 7.4 months (95% CI 6.1-8.7). There was a significant positive correlation between CA19-9 response and TTP (r = 0.66, p = 0.01). CA19-9 response was also significantly correlated with OS (r = 0.57, p < 0.01). The most common grade 3/4 toxicities were nausea/vomiting [12 patients (6.8%)]. Conclusions: Our results indicate that the capecitabine/cisplatin regimen is well tolerated and has moderate activity against advanced BTC. The CA19-9 response may be a suitable surrogate marker for patients with BTC who are treated with capecitabine/cisplatin.     

A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma

BACKGROUND/OBJECTIVES: Based on the synergistic effect between cisplatin and 5-fluorouracil (5-FU), and between 5-FU and interferon-alpha, we conducted a trial to assess the response rate and toxicity of the combination of cisplatin, 5-FU and interferon-alpha in patients with advanced esophageal cancer. METHODS: Patients with locally advanced or metastatic squamous cell or adenocarcinoma of the esophagus were eligible. No prior chemotherapy or interferon were allowed. Patients received cisplatin 80 mg/m(2) on day 1, 5-FU 750 mg/m(2)/day by continuous intravenous infusion for 5 days, and interferon-alpha 5 x 10(6) units/m(2)/day by subcutaneous injection on days 1-5 of each cycle. Cycles were repeated every 21 days for a total of 6 cycles. RESULTS: Forty patients were enrolled. Median age was 57.5 years (range 30-70). 33 had squamous carcinoma and 7 adenocarcinoma; 15 were male; the locoregional metastatic ratio was 1:39; median ECOG performance status was 2 (range 1-3). Grade 3-4 toxicities were: leukopenia (9 cases), thrombocytopenia (4), electrolyte imbalance (11), febrile neutropenia (11), vomiting (5), diarrhea (4), and mucositis (11). There were 3 early deaths, most probably related to therapy. Five patients (13%) achieved a complete response and 17 (42%) achieved a partial response, yielding an overall response rate of 55%. Response rates for squamous and adeno histology were 61% and 29%, respectively. Median survival was 6.4 months. CONCLUSION: The combination of cisplatin, 5-FU and interferon-alpha produces a high response rate in advanced squamous cell esophageal carcinoma, but with considerable toxicity. A modified combination of the above agents is presently being evaluated at our institution.